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Mycobacterium tuberculosis (Mtb) requires protein
secretion systems like ESX-1 for intracellular sur-
vival and virulence. The major virulence deter-
minant and ESX-1 substrate, EsxA, arrests phag-
osome maturation and lyses cell membranes,
resulting in tissue damage and necrosis that pro-
motes pathogen spread. To identify inhibitors of
Mtb protein secretion, we developed a fibroblast
survival assay exploiting this phenotype and
selected molecules that protect host cells from
Mtb-induced lysis without being bactericidal
in vitro. Hit compounds blocked EsxA secretion
and promoted phagosome maturation in macro-
phages, thus reducing bacterial loads. Target iden-
tification studies led to the discovery of BTP15, a
benzothiophene inhibitor of the histidine kinase
MprB that indirectly regulates ESX-1, and BBH7, a
benzyloxybenzylidene-hydrazine compound. BBH7
affects Mtb metal-ion homeostasis and revealed
zinc stress as an activating signal for EsxA secre-
tion. This screening approach extends the target
spectrum of small molecule libraries and will help
tackle the mounting problem of antibiotic-resistant
mycobacteria.
INTRODUCTION
Tuberculosis (TB), resulting from infection with Mycobacterium
tuberculosis (Mtb), is a serious global health problem account-
ing for 1.4 million deaths in 2011 (Lechartier et al., 2014). A
major reason for the high morbidity and mortality caused by
Mtb is the long duration of therapy and increasing multidrug
resistance. Alternative therapeutic agents are needed to com-
bat drug resistance. By screening compounds in vitro for
growth inhibition of Mtb, some progress has been made to-
ward clinically implementing bioactive molecules with new
mechanisms of action (Lechartier et al., 2014). However, given538 Cell Host & Microbe 16, 538–548, October 8, 2014 ª2014 Elseviethe high attrition rate of lead compounds in preclinical and
clinical development, alternative screening approaches are
needed. Traditional Mtb whole-cell screens often identify
different inhibitors, with the same mechanism of action, of
promiscuous targets, a problem that may be solved by
more sophisticated phenotypic screens (Lechartier et al.,
2014).
Targeting virulence protein secretion can extend the spec-
trum of existing antibacterial libraries (Feltcher et al., 2010).
This radically different approach has been applied to the
type III secretion systems (T3SSs) of Gram-negative bacte-
ria (Baron, 2010), which inject virulence determinants into
eukaryotic cells. Several structurally unrelated molecules
block T3SS protein secretion leading to attenuation and
bacterial clearance by the immune system (Izore´ et al.,
2011).
Mtb has two essential protein export systems that process
most of the secretome: the general secretory (Sec) and twin-
arginine (Tat) pathways (Braunstein et al., 2003). Five special-
ized ESX or type VII secretion systems export protein subsets
such as virulence determinants (Feltcher et al., 2010). Among
these, ESX-1 is a major, well-studied virulence protein secre-
tion apparatus comprising several transmembrane proteins,
ATPases, and essential accessory proteins. Additionally, there
are several key regulatory proteins that coregulate ESX-1
secretion. Various ESX-1-dependent substrates are essential
for host cell invasion, intracellular replication, and inhibition of
phagosome maturation (MacGurn and Cox, 2007; Stoop
et al., 2012). The best-understood ESX-1 substrate, EsxA, a
6 kDa protein, is capable of lysing cell membranes leading to
cytosolic escape and subsequent dissemination of Mtb (De
Leon et al., 2012). Loss of the ESX-1 genetic locus inMycobac-
terium bovis accounts for attenuation of the BCG vaccine
(Pym et al., 2002).
The regulatory and core proteins of the ESX-1 and house-
keeping secretion systems comprise a multitude of interesting
and thus far unexploited drug targets (Chen et al., 2010; Feltcher
et al., 2010). ESX-1 cannot be targeted by conventional whole-
cell screens since it is not essential for bacterial viability
in vitro. However, target-based screens have largely failed to
provide compounds with reasonable activity on Mtb (Lechartier
et al., 2014).r Inc.
Figure 1. Principle of Fibroblast-Based HTS
for Identification of Protein Secretion
Inhibitors
(A) Pipetting and incubation scheme of the FSA.
For drug screens, compounds were added to
empty 384-well plates followed by addition of
fibroblasts.
(B) Well-defined ESX-1 mutants are deficient in
killing fibroblasts (mean values and ± SD).
(C) Antimycobacterial compounds with intracel-
lular activity protect fibroblasts from Mtb-induced
cytotoxicity (10 mM, ± SD).
(D) Plate layout for HTS and identification scheme
for putative protein secretion inhibitors (see also
Figure S1).
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Targeting Mycobacterial Protein SecretionHere we developed a robust, whole-cell-based high-
throughput screen (HTS) broad enough to target essentially
all structural and regulatory ESX-1 components, yet specific
enough to exclude weak compounds. The screen exploited
the EsxA-dependent cytolytic activity of Mtb and uncovered
small molecules that promote survival of Mtb-infected hu-
man lung fibroblasts by inhibiting ESX-1-dependent protein
secretion. The transcriptomic signatures of the most potent
hits indicate functions beyond ESX-1 inhibition including
cell membrane transport, metal-ion homeostasis, and signal
transduction.Cell Host & Microbe 16, 538–548RESULTS
Development of a Lung Fibroblast-
Based HTS to Identify Protein
Secretion Inhibitors
To screen small molecule libraries for in-
hibitors of mycobacterial protein secre-
tion, we exploited the cytotoxicity of Mtb
for eukaryotic cells at high multiplicities
of infection (MOIs) as described by Hsu
et al. and Takii et al. (Hsu et al., 2003; Takii
et al., 2002). As proof of principle, MRC-5
lung fibroblasts were infected with the
wild-type Erdman strain and well-defined
attenuated mutants deficient in ESX-1
secretion followed by quantification of
metabolicactivity infibroblasts (Figure1A).
Wild-typeMtbwashighly cytotoxic,mark-
edly decreasing fluorescence compared
touninfectedcells in thisfibroblast survival
assay (FSA; Figure 1B). TheDRD1mutant,
lacking core genes in the ESX-1 locus, as
well as the Tn::pe35 mutant that does
not produce EsxA due to an upstream
transposon insertion, failed to lyse MRC-
5 fibroblasts. Furthermore, infection with
a deletion mutant of the PhoPR two-
component regulatory system or with a
DespA mutant led to significantly less
cytotoxicity due to impaired EsxA secre-
tion (Figure 1B) (Chen et al., 2013; Gon-
zalo-Asensio et al., 2008).We also tested several compounds with known antimycobac-
terial activity for their ability to protect MRC-5 cells from Mtb-
induced cell death. As expected, drugs with intracellular activity
(rifampicin, isoniazid, linezolid, and moxifloxacin) were highly
protective, whereas aminoglycosides (streptomycin and kana-
mycin), which fail to penetrate MRC-5 cells, were not (Figure 1C).
Since the assay endpoint is survival of eukaryotic cells, we tested
host-modifying drugs that have been shown to reduce intracel-
lular bacterial load by inhibiting host kinases such as BCR-Abl,
Akt, or the secreted mycobacterial kinase PknG (Lechartier
et al., 2014). None of these compounds protected fibroblasts, October 8, 2014 ª2014 Elsevier Inc. 539
Figure 2. Outcome of Primary and Confirmatory Screens
(A) Hit rate of FSA and REMA in primary and confirmatory screens.
(B) Potency of 55 FSA hit compounds (5 mM) in comparison to rifampicin
(5 mg/ml) and DMSO controls. Core structures of three most abundant
scaffolds.
(C) BTP15 and BBH7 protect fibroblasts from Mtb-induced killing in a dose-
dependent manner (± SD).
(D) BTP15 has no influence on GFP expression byMtb indicating that BTP15 is
not bactericidal in fibroblasts (5 mM, ± SD), whereas BBH7 reduces the GFP
signal comparable to rifampicin-treated fibroblasts (see also Figure S2).
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Targeting Mycobacterial Protein Secretionfrom Mtb-induced host cell lysis (Figure S1A available online).
Reducing theMOI led to aminor protective effect of some kinase
inhibitors (Figure S1A) indicating that their inactivity in the
FSA is primarily due to the choice of cell: fibroblasts versus
macrophages.
The FSA was adapted for 384-well plates giving a Z0-factor >
0.5 with rifampicin and DMSO as controls (Figure S1B). To distin-
guish between antivirulence compounds and growth-inhibitory
drugs, all compounds were counterscreened against Mtb in
the resazurin reduction microtiter assay (REMA). A putative pro-
tein secretion inhibitor was defined as a hit compound that pro-
tected fibroblasts from Mtb-induced cell death in the FSA
without affecting bacterial growth in the REMA (Figure 1D).540 Cell Host & Microbe 16, 538–548, October 8, 2014 ª2014 ElsevieOutcome of the Primary and Confirmatory Screens
A proprietary library of 10,880 synthetic compounds was
screened at a concentration of 5 mM leading to the identification
of 450 compounds that inhibited mycobacterial growth in the
REMA (Figure 2A). A total of 137 compounds were protective
in the FSA, and 46 compounds were active in both assays,
indicating that only 10% of the REMA hit compounds had intra-
cellular activity and were noncytotoxic for fibroblasts. After a
confirmatory screen, 55 of the 91 compounds, which impacted
virulence without affecting mycobacterial growth in the primary
screen, were validated as true hits (Figure 2A). Cheminformatic
analysis identified six clusters and nine singletons. Figure 2B
correlates the potency of these hits to the controls and displays
the three most abundant core structures. Of note, several
analogs of the benzyloxybenzylidene-hydrazines and the benzo-
thiophenes were almost as efficient as rifampicin in protecting
fibroblasts from Mtb-induced cell death.
For further studies, we selected a benzyloxybenzylidene-hy-
drazine compound (BBH7) and a benzothiophene compound
(BTP15; Figure S2A) with particularly good FSA activity and a
favorable cytotoxicity profile. Both compounds protected fibro-
blasts in a dose-dependent manner (Figure 2C) with an IC50 of
2.4 mM for BBH7 and 1.2 mM for BTP15, while no growth inhibi-
tion of Mtb was observed in vitro at 25 mM concentration (Fig-
ure S2B). TheMIC99 for several other mycobacteria and bacterial
pathogens was > 100 mM for both compounds (Figure S2C).
Intracellular antimycobacterial activity was determined by quan-
tifying Mtb expressing GFP in infected fibroblasts, and here the
compounds behaved divergently. BTP15-treated bacteria
showed GFP fluorescence comparable to the untreated control,
whereas no fluorescence was detected in the BBH7- and rifam-
picin-treated samples (Figure 2D). These data demonstrate that
BTP15 did not affect bacterial viability in the FSA, yet was highly
protective for fibroblasts exposed to Mtb, whereas BBH7 is a
potent inhibitor of intracellular growth.
BBH7 and BTP15 Inhibit Mycobacterial Protein
Secretion at Nanomolar Concentrations
The main aim of the FSA is to identify potential inhibitors of
ESX-1. We exposed Mtb cultures to the compounds, harvested
the culture filtrates, and quantified EsxA by immunoblotting.
Intriguingly, both compounds showed dose-dependent secre-
tion inhibition of this major virulence protein (Figure 3). We also
quantified Ag85 complex proteins, since these are Tat-depen-
dent substrates. At 5 mM, BBH7 fully blocked Ag85 secretion.
For BTP15 we observed a different pattern as, at concentrations
% 10 mM, Ag85 secretionwas only slightly affected at best. How-
ever, 20 mM BTP15 reduced Ag85 secretion and blocked EsxA
secretion fully (Figure 3).
BTP15 Deregulates Genes Controlled by Two-
Component Regulatory Systems
RNA-seq experiments with compound-treated Mtb provided
mechanistic insight from specific transcriptomic signatures.
Only 35 genes were differentially regulated when Mtb was
exposed to 5 mM of BTP15 (Table S1). Surprisingly, all 18 signif-
icantly downregulated genes were in the DosR (DevR) regulon
(Table S1; Figure 4A). This hypoxia-induced regulon requires
the two-component response regulator DosRS, which enablesr Inc.
Figure 3. BTP15 and BBH7 Affect EsxA Secretion of Mtb
Bacteria were exposed to different concentrations of compound. After 4 days
EsxA, Ag85, and GroEL (cell lysis control) were detected by immunoblotting
culture filtrate (CF) and cell lysate (CL).
Cell Host & Microbe
Targeting Mycobacterial Protein Secretionthe bacteria to enter a ‘‘dormant’’ nonreplicative state ensuring
long-term intracellular survival and latency (Park et al., 2003).
InMtb the response regulators PhoPR and MprAB are known
to link the DosR regulon and transcriptional regulation of the
ESX-1 secretion system via the distal espACD locus (Gonzalo-
Asensio et al., 2008; Pang et al., 2007, 2013). Deletion ofmprAB
leads to upregulation of espA and reduced EsxA secretion (Pang
et al., 2013). In the primary RNA-seq experiment, espA was up-
regulated below the threshold of 2, but on analysis by qRT-PCR,
espA was among the genes with > 2-fold differential regulation
(Figure 4A). Thus, reduced EsxA secretion and the subsequent
loss of virulence observed could be caused by deregulation of
the espACD locus. We then quantified transcription levels of
the regulatory genes dosR, phoP, and mprA after exposure to
BTP15. Interestingly,mprA expression was significantly downre-
gulated after 24 and 48 hr of treatment (Figure 4B). BTP15
(10 mM) also decreased mprB transcript levels 3-fold after
48 hr exposure (Figure S3A). Since there is considerable overlap
among DosR- and MprA-regulated genes, we compared the
BTP15 RNA-seq transcript analysis with published gene expres-
sion data onmprAB deletion mutants and found that the majority
of the 35 deregulated genes (highlighted in Table S1) were alsoCell Hosdifferentially regulated in this mutant under different conditions
(He et al., 2006; Pang et al., 2007).
BTP15 Is a Kinase Inhibitor that Inhibits MprB
Autophosphorylation In Vitro
Having found that treatment of Mtb with BTP15 leads to dereg-
ulation of genes controlled by two-component regulatory sys-
tems, notably MprAB, we reasoned that the compound might
directly affect ATP-dependent signal-transducing histidine ki-
nases. Studying histidine phosphorylation is extremely chal-
lenging due to the chemical instability of this posttranscriptional
modification (Kee and Muir, 2012). An MprB autophosphoryla-
tion assay was established using purified truncated MprB as
described (Zahrt et al., 2003). Relatively large amounts of
MprB (25 mM) were needed to detect the MprB phosphohistidine
(Figure 4C), as is common for histidine kinase phosphorylation
assays (Saini and Tyagi, 2005). Nonetheless, we demonstrated
dose-dependent inhibition of MprB autophosphorylation by
BTP15 (Figure 4D), but could not accurately determine the IC50
value due to the large amount of enzyme used. The nonhydrolyz-
able ATP analog AMP-PNP can be employed to estimate the
potency and specificity of histidine kinase inhibitors having
high in vitro IC50 values (Gilmour et al., 2005). When 10 mM
AMP-PNP (343 the in vitro IC50 of BTP15) was used, only
incomplete reduction of the phosphohistidine signal was seen,
whereas 1 mM AMP-PNP had no effect on autophosphorylation
(Figure 4D), indicating that BTP15 is a much stronger inhibitor of
MprB autophosphorylation than the ATP analog.
BBH7 Has a Pleiotropic Inhibitory Effect on
Mycobacterial Protein Secretion
By immunoblotting, BBH7was found to impact two different pro-
tein secretion systems at concentrations% 5 mM (Figure 3); we
also observed a 50% reduction of total culture filtrate protein
when bacteria were exposed to 5 mM BBH7 (data not shown).
To appreciate its full impact on protein secretion we character-
ized and quantified the secretome of treated and untreated bac-
teria by LC/MS-MS. These data confirmed the inhibitory effect of
BBH7 on the ESX-1 secretion system (Table S2). In addition,
several substrates of the ESX-5 secretion system such as
EsxN, EsxM, PE25, and PPE41 were significantly reduced in
abundance upon treatment. Reduced secretion of virulence-
associated proteins of unknown export mechanism was uncov-
ered showing that BBH7 affects several independent lines ofMtb
pathogenicity (Table S2).
BBH7 Deregulates Several Transmembrane ATPases
and Alters Mycobacterial Cell-Wall Permeability
Since BBH7 substantially impacted mycobacterial protein
secretion, we expected major changes in theMtb transcriptome
after treatment. Indeed, RNA-seq experiments revealed 144
differentially regulated genes (R 2-fold) upon exposure to
BBH7. Of these, 121 were upregulated, and the gene expression
signature mirrors changes primarily associated with cell-wall
processes and transport (Figures 5A and S4; Table S3). We
found positive regulation of the ESX transmembrane ATPase
genes eccCa1/eccCb1 and eccA5/eccE5 in response to altered
ESX-1- and ESX-5-dependent protein secretion. In addition,
strong upregulation of the P-type ATPase genes ctpC andt & Microbe 16, 538–548, October 8, 2014 ª2014 Elsevier Inc. 541
Figure 4. Kinase Inhibitor BTP15 Deregu-
lates Genes of the MprAB Regulon
(A) qRT-PCR of BTP15-treated samples. BTP15
leads to downregulation (> 1.5-fold) of DosR/
MprAB-associated genes and upregulation
(> 2-fold) of espA (± SD).
(B) Transcriptional levels of three two-component
regulatory genes followed by qRT-PCR at three
different time points after treatment with two
different concentrations. BTP15 downregulates
mprA after 24 and 48 hr of treatment (± SD).
(C) Coomassie blue-stained SDS-PAGE of
affinity-purified MprB and autophosphorylation of
MprB after incubation with [g-32P]ATP detected by
autoradiography.
(D) 25 mM of MprB was treated with BTP15, and
incorporation of 32P was quantified by scintillation
counting. BTP15 leads to a dose-dependent inhi-
bition of autophosphorylation. Nonhydrolysable
AMP-PNP was used as a control at 1 and 10 mM
(± SD) (see also Figure S3; Table S1).
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Targeting Mycobacterial Protein SecretionctpG indicated disturbed cell-membrane/cell-wall transport not
only for secreted proteins, but also for ions such as zinc and cop-
per. Several other signs for metal-ion overload were observed:
strong upregulation of the metallothionein mymT, the multicop-
per oxidase mmcO, the copper-dependent regulator ricR, and
the RicR-regulated gene lpqS, as well as deregulation of the
zinc stress-responsive genes cadI, rv1993, cysK2, esxG, and
esxH (Figure 4A; Table S3) (Botella et al., 2011; Serafini et al.,
2013). Indirect targets for metal-ion toxicity are Fe-S proteins,
explaining the upregulation of the Fe-S cluster biogenesis
operon SUF (rv1462–rv1466), and DNA damage leading to a
LexA-driven transcriptional response (Rowland and Niederweis,
2012).
To investigate whether BBH7 alters mycobacterial outer
membrane permeability, which might explain the transcrip-
tomic pattern associated with metal-ion toxicity, we performed542 Cell Host & Microbe 16, 538–548, October 8, 2014 ª2014 Elsevier Inc.ethidium bromide (EtBr) uptake assays
after treatment with the compounds of
interest. Indeed, BBH7 treatment was
found to increase EtBr accumulation and
fluorescence, a sign of perturbed mem-
brane permeability (Figure 5B). This was
not observed with BTP15. Interestingly,
BBH7 concentrations as high as 25 mM
had no impact on the activity of first- and
second-line TB drugs (Figure S5).
Zinc Stress Augments EsxA
Secretion
Having established that BBH7 treatment
leads to transcriptional signs of zinc and
copper stress, we surmised that intracel-
lular metal-ion stress might be the link
to inhibition of mycobacterial protein
secretion. Thus, we stressed Mtb with
physiological concentrations of zinc or
copper, as encountered in the phago-
some, and determined EsxA secretionlevels. Surprisingly, growing cells in media containing elevated
levels of ZnSO4 led to a significant and dose-dependent increase
of EsxA secretion, whereas Ag85 secretion remained unchanged
(Figure 5C). In the presence of 500 mM zinc, a concentration
measured in Mtb-infected macrophages (Botella et al., 2011), a
6-fold increase in EsxA secretion was observed (Figure 5C, lower
panel). Elevated concentrations of copper had no effect on EsxA
secretion. These findings indicate that BBH7 does not alter
mycobacterial protein secretion by zinc or copper intoxication.
Furthermore, we report an environmental signal (elevated zinc
levels) that augments EsxA secretion.
Since bacterial transport mechanisms depend on the proton
motive force, which is linked to intracellular ATP levels, the intra-
cellular ATP concentration was measured after BBH7 treatment.
Unlike treatment with the ATP synthase inhibitor bedaquiline
(BDQ), ATP levels were not reduced by BBH7 (Figure 5D). To
Figure 5. BBH7 Induces Several P-type-
ATPases and Alters Outer Membrane
Permeability
(A) Selection of up- and downregulated genes
upon exposure to BBH7 (5 mM).
(B) BBH7 treatment (10 mM) leads to increased
EtBr uptake indicating altered outer membrane
permeability. Representative example of three
individual experiments.
(C) Addition of zinc strongly induces EsxA
secretion in a dose-dependent manner. The Tat
substrate Ag85 is not affected by this treatment.
Band intensity of EsxA in the CF was quantified in
the lower panel (CF, culture filtrate; CL, cell
lysate; representative example of three individual
experiments).
(D) BBH7 and BTP15 (10 mM) have no impact on
ATP levels of Mtb; the ATP synthase inhibitor be-
daquiline (BDQ, 60 ng/ml) was used as a control.
Relative light units (RLUs) were adjusted to OD
values (± SD) (see also Figures S4 and S5; Tables
S2 and S3).
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wall inhibitors, we investigated whether such compounds affect
EsxA secretion. Isoniazid and ethambutol, as well as the thiourea
compounds ethionamide and thiacetazone, had no effect on
EsxA secretion at 0.53MIC (Figure S4C). At 53MIC, detection
of the cytosolic heat-shock protein GroEL in the culture filtrate
indicated cell lysis, which was not observed after BBH7 and
BTP15 treatment.
Taken together, these results indicate a mechanism of action
for BBH7, which alters cell-wall permeability for both export of
proteins and import of small molecules, leading to strong upre-
gulation of genes associated with metal-ion overload. However,
blockage of EsxA secretion by BBH7 does not seem to be
caused by zinc/copper intoxication or ATP depletion.
BBH7 and BTP15 Reduce Intracellular Bacterial Load
and Promote Phagolysosomal Fusion in Mtb-Infected
THP-1 Macrophages
Using GFP-expressing Mtb we had shown that BBH7 strongly
affects viability of intracellular bacteria in MRC-5 fibroblasts,Cell Host & Microbe 16, 538–548whereas BTP15 does not (Figure 2D).
Since the role of fibroblasts in in vivo in-
fections is not clear, we also investigated
the activity of the compounds by infecting
activated THP-1macrophages and quan-
tifying both surviving macrophages and
intracellular fluorescent mycobacteria.
Treatment with BBH7 and BTP15 pro-
tected THP-1 cells from Mtb-induced
cell death (Figure 6A) and greatly reduced
the intracellular bacterial load (Figures 6B
and 6C). Since the ESX-1 secretion
system plays a decisive role in the arrest
of phagosome maturation in Mtb-in-
fected macrophages (MacGurn and
Cox, 2007), we investigated whether
BBH7 andBTP15 can reverse this pheno-type. Activated THP-1 macrophages were infected at an MOI
of 0.5 with Mtb expressing GFP and treated for 7 days. Subse-
quently, acidic compartments were stained with Lysotracker
Red, and colocalization of the dyewith fluorescent mycobacteria
was quantified by confocal microscopy. Treated bacteria were
found in acidic compartments at significantly higher levels
than untreated bacteria (Figures 6D and 6E) indicating that
reduction of intracellular bacterial load in macrophages is pri-
marily achieved through inhibition of Mtb-induced phagosome
maturation arrest.
DISCUSSION
In this investigation, we developed and validated a phenotypic
drug screen based on ESX-1 secretion-dependent cytotoxicity
of Mtb. A HTS of > 10,000 small molecules identified two series
of compounds that significantly reduced secretion of EsxA
at nanomolar concentrations without affecting mycobacterial
growth in vitro, the benzothiophenes and benzyloxybenzyli-
dene-hydrazines. In addition, less potent hit compounds derived, October 8, 2014 ª2014 Elsevier Inc. 543
Figure 6. BTP15 and BBH7 Promote Phago-
lysosomal Fusion and Reduce Bacterial
Load in Activated THP-1 Macrophages
(A) Survival of activated THP-1 macrophages was
quantified as performed with MRC-5 lung fibro-
blasts. Both compounds (10 mM) protect the cells
from Mtb-induced cytotoxicity.
(B andC)Mtb-GFPwas quantified inside activated
THP-1 cells after treatment with BBH7 and BTP15
(10 mM) as described in Experimental Procedures.
Both compounds significantly reduce the intra-
cellular bacterial load. For BTP15, this contrasts
with treatment of infected fibroblasts where intra-
cellular replication is not affected (Figure 2D).
Scale bar, 100 mm.
(D and E) Confocal microscopy of infected THP-1
macrophages after treatment with two com-
pounds (10 mM) or vehicle (DMSO). After 7 days,
acidic compartments were stained with Lyso-
tracker Red, and colocalization of Mtb-GFP
with these compartments was quantified (scale
bar, 20 mm). Both compounds promote phag-
olysosomal fusion to higher levels than DMSO-
treated bacteria. ***p% 0.001, **p% 0.01 (± SD).
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compounds impacted ESX-1 function (data not shown). This in-
dicates that by selecting for hits that abrogate cytotoxicity of
Mtb, the chance of finding inhibitors of ESX-1-dependent protein
secretion is relatively high. The reason for this may lie in the na-
ture of the screen itself;Mtb-induced host cell lysis at highMOI is
almost exclusively associated with secretion of EsxA. Screening
deep transposon libraries for mutants with impaired cytolytic ac-
tivity primarily detected insertions in genes required for EsxA
secretion, thus highlighting the importance of this virulence
determinant (Gao et al., 2004; Hsu et al., 2003). Another key fac-
tor for selectivity of the bioassay is our choice of lung fibroblasts
for the quantification of Mtb-induced cell death. These nonpro-
fessional phagocytes fail to detect host-modifying agents that
reduce the intracellular burden ofMtb in macrophages (Lechart-
ier et al., 2014). This feature may be beneficial for target identifi-
cation of these antivirulence drugs.
The benzothiophene BTP15 is a kinase inhibitor that affects
EsxA secretion most likely by deregulating the espACD operon.
Several transcriptional regulators control ESX-1-dependent
secretion by binding to this operon that is not part of the ESX-
1 region, but nonetheless encodes EsxA cosecreted proteins
(Blasco et al., 2012; Gonzalo-Asensio et al., 2008; Pang et al.,
2013). An mprAB mutant displayed upregulation of espA and
greatly reduced EsxA secretion (Pang et al., 2013). Furthermore,544 Cell Host & Microbe 16, 538–548, October 8, 2014 ª2014 Elsevier Inc.MprA coregulates several DosR-regu-
lated genes and SigE (Pang et al., 2007).
BTP15 treatment deregulates a similar
set of genes and inhibits MprB auto-
phosphorylation in vitro. Thus, the two-
component regulatory system MprAB
is the probable BTP15 target. MprAB
is clearly associated with virulence
since the corresponding mutants show
impaired survival in vivo, particularly dur-ing the chronic stage of infection (Zahrt and Deretic, 2001). Mac-
rophages infected with a DmprAB strain elicit significantly lower
levels of tumor necrosis factor alpha and interleukin 1b similar to
Mtb strains deleted for espACD or the ESX-1 region (Pang et al.,
2013). MprAB also seems to regulate the ESX-1 region itself
since the mprAB mutant fails to secrete EspB, a protein that is
not influenced by the espACD operon (Chen et al., 2013; Pang
et al., 2013). We also found inhibition of EspB secretion upon
BTP15 treatment (Figure S3B), accompanied by greater attenu-
ation than seen with a DespA mutant in the FSA. However, in
contrast to BTP15-treated macrophages, which show reduced
intracellular bacterial load, loss of mprAB does not reduce the
number of intracellular bacteria in activated macrophages (Zahrt
and Deretic, 2001). Low expression levels of dosR, phoP, and
mprA were revealed by qRT-PCR experiments, although subtle
transcriptional changes during drug treatment may not have
been detected. Many of the ESX-1 regulatory genes are induced
during intracellular infection, thus BTP15 may have an extended
impact on virulence gene expression insidemacrophages and fi-
broblasts, explaining the discrepancy between the intracellular
behavior of the DmprAB mutant and BTP15-treated bacteria.
Bacterial histidine sensor kinases and two-component reg-
ulatory systems are indeed interesting drug targets. Potent inhib-
itors with good in vivo activity have been generated for Gram-
negative pathogens (Rasko et al., 2008). Deletions of these
Figure 7. Model for Zinc-Induced EsxA
Secretion and Implications for BBH7
Function
(A) After phagocytozing Mtb macrophages recruit
heavy metal-transporting ATPases like ATP7A
to the phagosomal membrane leading to intra-
phagosomal accumulation of toxic amounts
of copper and zinc. This triggers a mycobacterial
response involving upregulation of P-type
ATPases (CtpC/CtpG) and metal-chelating pro-
teins to clear intracellular copper and zinc. In
addition, elevated zinc concentrations induce
secretion of EsxA leading to subsequent phag-
osomal damage and ion efflux thus providing a
second line of defense against host-driven heavy
metal intoxication.
(B) Treatment with BBH7 alters mycobacterial
outer membrane permeability leading to tran-
scriptional signs of copper and zinc stress. CtpC and CtpG will promote heavy metal efflux into the phagosomal vacuole. In parallel, the ESX-1-translocating
ATPases EccCa1 and EccCb1 are upregulated; however, EsxA secretion is blocked, probably leading to phagosomal integrity, further heavy metal accumulation
in the phagosome, and poisoning of Mtb.
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impressively by the Mtb DphoPR mutant, which is currently be-
ing developed as a live TB vaccine (Gonzalo-Asensio et al.,
2008). Histidine kinase domains are structurally distinct from eu-
karyotic serine, threonine, and tyrosine kinases, and this may
enable kinase inhibitors with selective antibacterial activity to
be developed (Kee andMuir, 2012). However, unlike serine, thre-
onine, and tyrosine kinases, where a plethora of in vitro and
in vivo tools are available, histidine kinase research is handi-
capped by a lack of biochemical tools, largely due to the chem-
ical instability of this posttranslational modification (Kee and
Muir, 2012). Nevertheless, with the FSA we provide a validated
assay for targeting membrane-bound kinases and other ESX-1
regulatory proteins with small molecules.
While there is considerable knowledge of the proteins involved
in transmembrane export of substrates, nothing is known of the
fate of proteins once translocated to the periplasm, nor of the
mechanism for export through themycomembrane. Again, puta-
tive pore and channel proteins involved in these processes may
be interesting drug targets due to their extracytoplasmic loca-
tion, which may facilitate drug accessibility. This notion is sup-
ported by the discovery of a broad-spectrum inhibitor of three
unrelated secretion systems in Gram-negative pathogens that
is believed to target outer-membrane pore proteins shared by
several translocation systems (Felise et al., 2008). With BBH7
we identified a pleiotropic inhibitor of mycobacterial protein
secretion. However, the gene expression signature following
exposure to BBH7, with strong upregulation of several P-type
ATPases as well as altered EtBr uptake in treated bacteria, sug-
gests disturbed export not only for proteins, but also for smaller
molecules. This makes a common pore structure exclusively
dedicated to protein transport through the cell envelope an un-
likely target of BBH7. Rather, it is conceivable that this com-
pound has a more general impact on processes involved in
cell-wall biogenesis.
Another possiblemechanism of action for BBH7 is depletion of
the ATP source for themembrane-bound transport ATPases that
is linked to the proton-motive force. Although some protono-
phores also inhibit bacterial protein translocation, we provideCell Hosseveral independent data sets that functionally separate BBH7.
First, protonophores are known to deplete the intracellular ATP
pool of Mtb rapidly (Boshoff et al., 2004), which was not the
case for treatment with BBH7. Second, the transcriptional signa-
ture of protonophore compounds, with strong upregulation of
the cyd-operon and genes of the respiratory chain (Boshoff
et al., 2004), is distinct from the BBH7 response. Third, unlike
BBH7, the nonselective protonophores are highly cytotoxic for
Mtb (Brown and Parish, 2008) as well as for eukaryotic cells.
There are distinct signs of zinc and copper stress in bacteria
exposed to BBH7. Intraphagosomal zinc/copper accumulation
as a means for host defense has emerged as an exciting field
inmycobacterial research (Botella et al., 2011; Rowland and Nie-
derweis, 2012). In this context, our finding of zinc-enhanced
secretion of EsxA might represent a mycobacterial defense
mechanism to counteract heavy metal toxicity. Until now, the
environmental signals inducing secretion of EsxA have been
poorly understood. We propose a model where, after phagocy-
tosis, the cation exporters CtpC and CtpG are upregulated to
rapidly relieve cytosolic zinc stress (Figure 7A). However, the
phagosome is a closed environment, so the initial upregulation
of P-type ATPases will reduce zinc levels in the bacterial cytosol,
but not in the phagosome. More sustained alleviation of metal-
ion stress may be via EsxA-mediated lysis of the phagosomal
membrane (Figure 7A). In fact, EsxA-dependent leakage of po-
tassium ions and efflux of charged fluorophores from phagoso-
mal membranes was recently reported (De Leon et al., 2012).
Pore-forming toxin-dependent ion efflux from the phagosome
or the host cell membrane is a hallmark of most intracellular bac-
terial pathogens (Gonzalez et al., 2008).
This model also implies a dual and probably synergistic effect
of BBH7 on mycobacterial virulence. BBH7 increases outer
membrane permeability and leads to heavy metal stress. The
bacterium responds by upregulating the EsxA-translocating
ATPases EccCb1 and EccCa1; however, EsxA secretion is
blocked by BBH7, which leaves the phagosomal membrane
intact and possibly leads to further accumulation of toxic sub-
stances in the phagosome (Figure 7B). This mechanism may
explain the high rate of phagocytosed bacteria colocalizingt & Microbe 16, 538–548, October 8, 2014 ª2014 Elsevier Inc. 545
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observed in BBH7-treated macrophages and fibroblasts. Of
note, there is evidence that the ESX-3 secretion system is
involved in zinc homeostasis of Mtb (Serafini et al., 2013).
Thus, interference with ESX-3 activity by BBH7 may cause the
zinc stress observed.
The molecules identified in this work would have escaped
detection by conventional whole-cell screens. By selecting for
a specific phenotype strongly associated with mycobacterial
virulence, the hit spectrum of a given library can be extended
as demonstrated here. We also show that molecules protecting
eukaryotic cells fromMtb-induced cytotoxicity may affect myco-
bacterial virulence beyond EsxA secretion (dormancy, small
molecule influx). The data indicate that antivirulence drugs are
capable of reducing the intracellular bacterial load by inducing
phagosomal processing in professional phagocytes at levels
similar to first-line drugs (Ramachandra et al., 2005).
Our assay format provides both a rapid readout and informa-
tion about the bactericidality, antivirulence effect, cytotoxicity,
and intracellular activity of the hits. Screening novel compound
libraries or rescreening existing collections using the FSA may
identify additional hits, with mechanisms of action appropriate
for lead optimization. Furthermore, compounds from other intra-
cellular screens showing a discrepancy between intracellular
IC50 and MIC in broth should be tested for inhibition of EsxA
secretion, which may facilitate identification of their targets.
Finally, our robust screening strategy based on inhibition of
pathogen-driven host cell toxicity could also be adopted for anti-
virulence drug screens targeting toxin-secreting bacteria such
as Clostridium difficile where alternative treatment approaches
are urgently needed.
EXPERIMENTAL PROCEDURES
Bacterial Culture Conditions and Eukaryotic Cell Lines
Full description of experimental procedures and reagents used can be found in
Supplemental Information. Mycobacterial strains were routinely grown in Mid-
dlebrook 7H9 broth (supplemented with 0.2% glycerol, 10% ADC, and 0.05%
Tween 80) or in Sauton’s medium for culture filtrate analysis. ESX-1 mutants
used for proof of principle studies were H37Rv-DRD1, Mtb Erdman
Tn::pe35, Mtb Erdman-DespA (Chen et al., 2013), and Mtb-MT103 DphoP
(Gonzalo-Asensio et al., 2008). MRC-5 human lung fibroblasts from the Coriell
Institute for Medical Research were grown in MEM medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 1% nonessential amino
acids, and 1 mM sodium pyruvate. THP-1 macrophages were grown in
RPMI medium supplemented with 10% FBS. Both cell lines were grown at
37C with 5% CO2.
HTS
Library compounds were preplated into CellBIND 384-well microplates (Corn-
ing Life Sciences) at a concentration of 50 mM in 5 ml of 5%DMSO.MRC-5 cells
grown to late log phase were harvested and seeded at 4,000 cells/well in a vol-
ume of 35 ml using an automated microplate dispenser (Multidrop Combi,
Thermo Scientific). Cells were allowed to adhere for 3 hr before washed, and
midlogarithmic-phase Mtb Erdman cells were added to the assay plates at
an MOI of 10 in 10 ml of MEM medium. Plates were sealed and incubated at
37C under 5% CO2. Rifampicin (5 mg/ml) was used as a control (see Figure 1)
for assay plate layout. After 72 hr, plates were left at room temperature (RT) for
1 hr, and 5 ml of PrestoBlue Cell Viability Reagent (Life Technologies) was
added. After 1 hr at RT, fluorescence was measured in a Tecan Infinite
M200 plate reader (excitation 570 nm, emission 590 nm; fluorescence gener-
ated by the bacteria was negligible). REMA assays were performed in 7H9
broth using a starting OD of 0.0001, a 7-day incubation period, and a final546 Cell Host & Microbe 16, 538–548, October 8, 2014 ª2014 Elsevievolume of 10% resazurin (0.025% w/v). Z0-factor determinations were as
described in Supplemental Information. Replicates were considered as hits
if their values were superior to the mean of the negative control values plus
three standard deviations. The final score was themean value of the replicates.
Immunoblots and Secretome Analysis
Protein preparation and immunoblots were performed as described recently
(Chen et al., 2013). In brief, 30 ml of bacteria grown to midlogarithmic phase
(OD600 of 0.6–0.7) in Sauton’s medium supplemented with 0.05% Tween 80
were centrifuged and resuspended in Sauton’s medium without Tween. Com-
pounds were added at concentrations as indicated, and cells were grown
further at 37C with shaking for 4 days. Cultures were harvested by centrifuga-
tion toobtainculturefiltrates andcell pellets.Culturefiltrateswere concentrated
100-fold in5kDacutoffVivaspincolumns (Sartorius).Cell lysateswereprepared
by bead beating bacterial pellets in lysis buffer with 100 mm glass beads.
For immunoblotting, 5 mg of protein was resolved by SDS-PAGE and trans-
ferred to nitrocellulose membranes. Membranes were blocked with TBS buffer
(3% milk powder) and incubated overnight with the desired primary antibody
diluted in TNT buffer supplemented with 1% BSA fraction V. Membranes
were washed with TNT, incubated with the appropriate secondary antibody
in TNT-BSA, washed again with TNT, and developed. GroEL2 was used as
lysis control for culture filtrates and loading control for cell lysates.
Protein preparation for secretome analysis, dimethyl labeling, and mass
spectrometry were performed as described in Supplemental Experimental
Procedures.
RNA Extraction, qRT-PCR, and RNA-seq
For transcriptomics, bacteria were grown under the same conditions as for
protein secretion assays. Drug exposure was 8 hr at 5 mM for RNA-seq exper-
iments and confirmatory qRT-PCR. RNAwas extractedwith TRIzol (Invitrogen)
and treated with DNase I (Roche) prior to library preparation or generation
of the cDNA template. cDNA was synthesized using the RevertAid First
Strand cDNA Synthesis Kit (Fermentas) using random hexamer primers.
cDNA corresponding to 10 ng of input RNAwas used in each RT-PCR reaction
supplemented with specific primer pairs (200 nM each) listed in Supplemental
Information and SYBR-Green Master Mix (Applied Biosystems). Quantitative
RT-PCR reactions were performed with the 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems) as follows: 50C for 2 min, 95C for 10 min, then 40
cycles of 95C for 15 s and 60C for 60 s. Melt curve analysis confirmed
specific amplification for each primer pair.
For the RNA-seq library preparation, 100 ng of total RNA was used in the
TruSeq Stranded mRNA LT Kit, according to the instructions provided by Illu-
mina. An aliquot was analyzed on Qubit (Life Technologies) and Fragment
Analyzer (Advanced Analytical) prior to sequencing on an Illumina HiSeq using
the TruSeq SR Cluster Generation Kit v3 and TruSeq SBS Kit v3. Data were
processed with the Illumina Pipeline Software v1.82. RNA-seq data were
deposited in the Gene Expression Omnibus (GEO) server at the National Cen-
ter for Biotechnology Information (NCBI).
Quantification of Intracellular ATP Levels and EtBr Uptake Assays
Bacteria were grown for 24 hr with test compounds, and the BacTiter-Glo
viability reagent (Promega) was used to quantify ATP levels as per the manu-
facturer’s recommendations. For EtBr uptake assays, bacteria were washed
with PBS containing 0.05% Tween 80, OD600 was adjusted to 0.4, and
100 ml were pipetted into black 96-well plates. EtBr was added (4 mM final
concentration), and fluorescence was read every 2 min at 545/600 nm.
Fluorescence Microscopy
THP-1 macrophages were activated on round 9 mm coverslips in 24-well
plates (105 cells/well) with 100 nM of phorbol-12-myristate-13-acetate for
72 hr. To quantify intracellularMtb Erdman-GFP, macrophages were infected
at an MOI of 2 for 12 hr. Cells were washed to remove unphagocytosed bac-
teria, and fresh medium containing compounds or DMSO was added. After in-
cubation for 4 days, cells were washed, fixed with 4%paraformaldehyde/PBS,
and stained with Dapi-Fluoromount-G (SouthernBiotech). Images were ac-
quired on a Zeiss LSM 700 using ZEN imaging software and Fiji processing
software. At least 40 fields of three separate monolayers were collected for im-
age processing and statistical analysis. For intracellular localization studies,r Inc.
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12 hr, extracellular bacteria were removed bywashing with PBS, and freshme-
dium containing compounds or DMSO was added. Incubation continued for a
total of 7 days with replacement of media plus compounds after 3 days. Fresh
medium containing 50 nM Lysotracker Red (Life Technologies) was added for
2 hr. Cells were washed and fixed as described above. Colocalization rates
of GFP-fluorescing phagosomes and Lysotracker Red were determined by
analyzing > 100 phagosomes from at least three separate monolayers.
Protein Purification and Kinase Inhibitor Assay
Proteins were purified as described (Rybniker et al., 2014). For autophosphor-
ylation assays, MprB lacking its N-terminal transmembrane domain was incu-
bated with [g-32P]ATP (10 mCi/ml, 3,000 Ci/mmol) in 50 mM Tris-HCl (pH 7.5),
50 mM KCl, and 20 mM MnCl2 for 1 hr. Reactions were stopped by heating in
SDS loading buffer for 5 min at 80C followed by sample separation using
SDS-PAGE. Gels were either stained with Coomassie brilliant blue or dried
for 2 hr at 60C in a Model 583 Gel Dryer (Bio-Rad) followed by exposure to
X-ray film overnight or counting of 32P incorporation into band equivalents
using an LS6500 Scintillation Counter (Beckman Coulter). For kinase inhibitor
assays, compounds were preincubated with MprB for 3 hr prior to addition of
[g-32P]ATP.
Statistical Analyses
Unpaired Student’s t tests were used throughout.
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